Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells

Slides:

Advertisements

Similar presentations

Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation Qing Ma, Dan Li, Roza Nurieva, Rebecca.

Advertisements

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation Michael Weber,

Stephanie J. Lee, Loretta A. Williams

Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.

Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:

Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,

Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation

Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease Robert Zeiser,

IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy

Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A

Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells

Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver Alina Schreder,

Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell.

Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J

Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.

Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.

LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.

Immune Tolerance to Self-Major Histocompatability Complex Class II Antigens after Bone Marrow Transplantation: Role of Regulatory T Cells Allan D. Hess,

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation Yang Wang, Dan Li, Dan Jones, Roland.

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality Kai Sun,

Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice Chien-Chun Steven Pai,

Evelyn C. Nieves, Tomomi Toubai, Daniel C

Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal Patricia A. Taylor,

Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens Hisaki Fujii,

Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses

Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels Chien-Chun Steven.

The Pentostatin Plus Cyclophosphamide Nonmyeloablative Regimen Induces Durable Host T Cell Functional Deficits and Prevents Murine Marrow Allograft Rejection

TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd Bettina P. Iliopoulou, PhD, Katie Hsu, MS, Antonio Pierini, MD, Gordon J. Freeman,

Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation Isabel Barao, Maite.

Stephanie J. Lee, Loretta A. Williams

T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice Denis R. Burger, Yvonne Parker, Kathryn.

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.

Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice Dapeng Wang, Yu Yu, Kelley Haarberg,

Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease Haruko Sugiyama,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

B7.2−/− Mature Dendritic Cells Generate T-Helper 2 and Regulatory T Donor Cells in Fetal Mice after In Utero Allogeneic Bone Marrow Transplantation Swati.

Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.

Interleukin 17 Is Not Required for Autoimmune-Mediated Pathologic Damage during Chronic Graft-versus-Host Disease Xiao Chen, Rupali Das, Richard Komorowski,

Treatment of Severe Refractory Acute Graft-versus-Host Disease of the Gastrointestinal Tract with Campath-1H Alessandro Busca, Franco Locatelli, Elisabetta.

Persistence of host dendritic cells after transplantation is associated with graft-versus- host disease Geoffrey W. Chan, Gullu Gorgun, Kenneth B. Miller,

CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease Philip R Streeter,

Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation Jian-Ming Li, Edmund K.

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect Shawn G Clouthier,

Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution Maria Gendelman, Maryam Yassai,

Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease Wonyoung Kim, Juyang.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.

Volume 37, Issue 2, Pages (August 2012)

Presentation transcript:

Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells Jason E. Foley, Jacopo Mariotti, Kaitlyn Ryan, Michael Eckhaus, Daniel H. Fowler Biology of Blood and Marrow Transplantation Volume 14, Issue 9, Pages 959-972 (September 2008) DOI: 10.1016/j.bbmt.2008.06.007 Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Delayed administration of Th2 cells improves balance of GVHD and GVT effects. B6-into-BALB/c BMT was performed (850 cGy host irradiation). Cohorts received donor marrow alone (“BMT”); marrow and host-type TS/A tumor cells (“TSA”); or marrow, tumor cells, and additional donor T cells (“GVHD”). Other cohorts received marrow, tumor cells, donor T cells, and additional donor CD4+ Th2 cells generated ex vivo in high-dose rapamycin (10 μM; administered on day 14 post-BMT); Th2 cells were generated from either wild-type donors (“Th2”) or IL-4-deficient donors (“Th2 4−/−”) or IL-10-deficient donors (“Th2 10−/−”). On day 19 post-BMT, lungs from treatment cohorts were removed to evaluate tumor burden; liver, stomach, small intestine, large intestine, cecum, and skin were harvested to assess GVHD. (A) For GVHD, each organ was scored on a scale of 0 to 4, with cumulative GVHD severity score shown (maximum value = 24). (B) For tumor burden, a semiquantitative determination of tumor cell infiltration was scored on a scale of 0 to 4; n = 7 subjects were evaluated in each cohort. Biology of Blood and Marrow Transplantation 2008 14, 959-972DOI: (10.1016/j.bbmt.2008.06.007) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Donor Th2 cells inhibit donor CD8+ T cell expansion after allogeneic BMT. B6-into-BALB/c BMT was performed (850 cGy host irradiation). Cohorts received donor marrow alone (“BMT”); marrow and TS/A tumor cells (“TSA”); or marrow, tumor cells, and additional donor T cells (“GVHD”). Other cohorts received marrow, tumor cells, donor T cells, and additional donor CD4+ Th2 cells generated from either wild-type donors (“Th2”) or IL-4 deficient donors (“Th2 4−/−”) or IL-10 deficient donors (“Th2 10−/−”). On day 19 post-BMT, spleen cells were isolated and the absolute number of donor CD8+ T cells (A) and CD4+ T cells (B) were calculated from flow cytometry data (cells per spleen, ×106). Data shown are mean ± SEM (n = 7 per cohort). Biology of Blood and Marrow Transplantation 2008 14, 959-972DOI: (10.1016/j.bbmt.2008.06.007) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 In vivo IL-2 administration abrogates Th2 cell therapy: histology analysis. B6-into-BALB/c BMT was performed (850 cGy host irradiation). Cohorts received donor marrow alone (“BMT”); marrow and TS/A tumor cells (“TSA”); marrow, tumor cells, and additional donor T cells (“GVHD”); or marrow, tumor cells, donor T cells, and IL-2 therapy (“GVHD+IL-2”; 50,000 I.U., twice a day from day 14 to day 18 post-BMT). Other cohorts received marrow, tumor cells, donor T cells, and donor Th2 cells on day 14 post-BMT either alone (“Th2”) or with IL-2 infusion (“Th2+IL-2”). On day 19 post-BMT, lungs from treatment cohorts were removed to evaluate tumor burden; liver, stomach, small intestine, large intestine, cecum, and skin were harvested to assess GVHD. (A) For GVHD, each organ was scored on a scale of 0 to 4, with cumulative GVHD score shown (maximum value = 24). (B) For tumor burden, a semiquantitative determination of tumor cell infiltration was scored on a scale of 0 to 4; n = 5 subjects were evaluated per cohort. Biology of Blood and Marrow Transplantation 2008 14, 959-972DOI: (10.1016/j.bbmt.2008.06.007) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Th2 cell inhibition of CD8+ T cell expansion is abrogated by IL-2. B6-into-BALB/c BMT was performed (850 cGy host irradiation). Cohorts received donor marrow alone (“BMT”); marrow and TS/A tumor cells (“TSA”); marrow, tumor cells, and additional donor T cells (“GVHD”); or marrow, tumor cells, donor T cells, and IL-2 therapy (“GVHD+IL-2”; 50,000 I.U., twice a day from day 14 to day 18 post-BMT). Other cohorts received marrow, tumor cells, donor T cells, and donor Th2 cells on day 14 post-BMT either alone (“Th2”) or with IL-2 infusion (“Th2+IL-2”). On day 19 post-BMT, spleen cells were isolated and the absolute number of donor CD8+ T cells (A) and CD4+ T cells (B) emanating from the initial allograft, and the absolute number of CD90.1+Th2 cells [C] were calculated from flow cytometry data (cells per spleen, ×106). Data shown are mean ± SEM (n = 5 per cohort). Biology of Blood and Marrow Transplantation 2008 14, 959-972DOI: (10.1016/j.bbmt.2008.06.007) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Host-type APC infusion abrogates Th2 cell anti-GVHD effect: histology. B6-into-BALB/c BMT was performed (850 cGy host irradiation). Cohorts received donor marrow (“BMT”); marrow and TS/A tumor cells (“TSA”); marrow, tumor cells, and donor T cells (“GVHD”); marrow, tumor cells, donor T cells, and donor-type APC (“GVHD + Donor DC”); or marrow, tumor cells, donor T cells and host-type APC (“GVHD + Host DC”). Other cohorts received marrow, tumor cells, donor T cells, and donor Th2 cells either alone (“Th2”; day 14 post-BMT), with donor-type APC (“Th2 + Donor DC”), or with host-type APC (“Th2 + Host DC”). On day 19 post-BMT, lungs from treatment cohorts were removed to evaluate tumor burden; liver, stomach, small intestine, large intestine, cecum, and skin were harvested to assess GVHD. (A) For GVHD, each organ was scored (scale = 0 to 4), with cumulative GVHD score shown (maximum value = 24). (B) For tumor burden, a semiquantitative determination of tumor cell infiltration was scored (scale = 0 to 4); n = 5 subjects were evaluated per cohort. Biology of Blood and Marrow Transplantation 2008 14, 959-972DOI: (10.1016/j.bbmt.2008.06.007) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 Host-type APC transfer abrogates Th2 cell therapy: donor T cell tracking. B6-into-BALB/c BMT was performed (850 cGy host irradiation). Cohorts received donor marrow alone (“BMT”); marrow and TS/A tumor cells (“TSA”); marrow, tumor cells, and additional donor T cells (“GVHD”); marrow, tumor cells, donor T cells, and donor-type APC (“GVHD + Donor DC”); or marrow, tumor cells, donor T cells and host-type APC (“GVHD + Host DC”). Other cohorts received marrow, tumor cells, donor T cells, and donor Th2 cells either alone (“Th2”; day 14 post-BMT), with donor-type APC (“Th2 + Donor DC”), or with host-type APC (“Th2 + Host DC”). On day 19 post-BMT, spleen cells were isolated and the absolute number of donor CD8+ T cells (A) and CD4+ T cells (B) emanating from the initial allograft, and the absolute number of CD90.1+Th2 cells [C] were calculated from flow cytometry data (cells per spleen, ×106). Data shown are mean ± SEM (n = 5 per cohort). Biology of Blood and Marrow Transplantation 2008 14, 959-972DOI: (10.1016/j.bbmt.2008.06.007) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions